Pharmacokinetic Disposition of Zidovudine during Pregnancy
Zidovudine pharmacokinetics was determined in three human immunodeficiency virus type I-seropositive women receiving zidovudine (200 mg orally every 4 h) from 19 to 39 weeks ofpregnancy and postpartum. Zidovudine concentrations were measured using high-pressure liquid chromatography, and pharmacokin...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1991-02, Vol.163 (2), p.226-232 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 232 |
|---|---|
| container_issue | 2 |
| container_start_page | 226 |
| container_title | The Journal of infectious diseases |
| container_volume | 163 |
| creator | Watts, D. Heather Brown, Zane A. Tartaglione, Teresa Burchett, Sandra K. Opheim, Kent Coombs, Robert Corey, Lawrence |
| description | Zidovudine pharmacokinetics was determined in three human immunodeficiency virus type I-seropositive women receiving zidovudine (200 mg orally every 4 h) from 19 to 39 weeks ofpregnancy and postpartum. Zidovudine concentrations were measured using high-pressure liquid chromatography, and pharmacokinetic analyses were done using model-independent methods. For the pregnant versus postpartum periods, peak zidovudine levels (mean ± 1 SD) were 3.9 ± 1.7 µmol/l versus 4.3 ± 0.04 µmol/l (P = .56); elimination half-lives were 1.3 ± 0.6 versus 1.0 ± 0.3 h (P = .41); areas under the concentration curve were 4.5 ± 1.0 µmol/l × hand 6.8 ± 0.5 µmol/l × h (P = .02); apparent total body clearances were 2.5 ± 0.6/1h/kg and 1.7 ± 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 ± 1.0 1/kg and 2.6 ± 0.81/kg (P = .07), respectively. Umbilical cord serum levels ranged from 113%–127% of maternal levels. No persistent adverse effects of zidovudine therapy were seen in the three women or their babies. |
| doi_str_mv | 10.1093/infdis/163.2.226 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_80429252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30122959</jstor_id><sourcerecordid>30122959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-e47758fad246f89830958b0eec2181f6ff17b9c99c22bca7bd25b0f584bf1ab53</originalsourceid><addsrcrecordid>eNqFkDtvFDEURi0ECkugp0GaAtHN5toePy4dCo9FRCJIIEVpLI_HDk52xxt7BpF_j9EsSUl1i_PdUxxCXlJYU0B-EscwxHJCJV-zNWPyEVlRwVUrJeWPyQqAsZZqxKfkWSnXANBxqY7IEUWtBagVeXv-0-addekmjn6Krnkfyz6VOMU0Nik0l3FIv-ahwmaYcxyvmvPsr0Y7urvn5Emw2-JfHO4x-fHxw_fTTXv29dPn03dnres0TK3vlBI62IF1MmjUHFDoHrx3jGoaZAhU9egQHWO9s6ofmOghCN31gdpe8GPyZvHuc7qdfZnMLhbnt1s7-jQXo6FjyAT775BWp0YFdQjL0OVUSvbB7HPc2XxnKJi_Xc3S1dSuhpnatb68OrjnfueHh4clZOWvD9wWZ7ch10JV8G_WoVQU1YPmukwp32MOlDEUWHm78Fgm__ue23xjpOJKmM3FpcFvX_Big8II_gftV5pj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15848970</pqid></control><display><type>article</type><title>Pharmacokinetic Disposition of Zidovudine during Pregnancy</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><creator>Watts, D. Heather ; Brown, Zane A. ; Tartaglione, Teresa ; Burchett, Sandra K. ; Opheim, Kent ; Coombs, Robert ; Corey, Lawrence</creator><creatorcontrib>Watts, D. Heather ; Brown, Zane A. ; Tartaglione, Teresa ; Burchett, Sandra K. ; Opheim, Kent ; Coombs, Robert ; Corey, Lawrence</creatorcontrib><description>Zidovudine pharmacokinetics was determined in three human immunodeficiency virus type I-seropositive women receiving zidovudine (200 mg orally every 4 h) from 19 to 39 weeks ofpregnancy and postpartum. Zidovudine concentrations were measured using high-pressure liquid chromatography, and pharmacokinetic analyses were done using model-independent methods. For the pregnant versus postpartum periods, peak zidovudine levels (mean ± 1 SD) were 3.9 ± 1.7 µmol/l versus 4.3 ± 0.04 µmol/l (P = .56); elimination half-lives were 1.3 ± 0.6 versus 1.0 ± 0.3 h (P = .41); areas under the concentration curve were 4.5 ± 1.0 µmol/l × hand 6.8 ± 0.5 µmol/l × h (P = .02); apparent total body clearances were 2.5 ± 0.6/1h/kg and 1.7 ± 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 ± 1.0 1/kg and 2.6 ± 0.81/kg (P = .07), respectively. Umbilical cord serum levels ranged from 113%–127% of maternal levels. No persistent adverse effects of zidovudine therapy were seen in the three women or their babies.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/163.2.226</identifier><identifier>PMID: 1988507</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University Chicago Press</publisher><subject>Adult ; AIDS ; AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antigens ; Antiviral agents ; Biological and medical sciences ; Blood ; Blood plasma ; Chromatography, High Pressure Liquid ; Dosage ; Female ; Fetal Blood - chemistry ; Half lives ; Half-Life ; HIV ; HIV Infections - metabolism ; HIV Infections - prevention & control ; Humans ; Infant, Newborn ; Infants ; Major Articles ; Medical sciences ; Pharmacokinetics ; Pharmacology. Drug treatments ; Postpartum Period - metabolism ; Pregnancy ; Pregnancy - metabolism ; Pregnancy Complications, Infectious - metabolism ; Zidovudine - pharmacokinetics ; Zidovudine - therapeutic use</subject><ispartof>The Journal of infectious diseases, 1991-02, Vol.163 (2), p.226-232</ispartof><rights>Copyright 1991 The University of Chicago</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-e47758fad246f89830958b0eec2181f6ff17b9c99c22bca7bd25b0f584bf1ab53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30122959$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30122959$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4967197$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1988507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Watts, D. Heather</creatorcontrib><creatorcontrib>Brown, Zane A.</creatorcontrib><creatorcontrib>Tartaglione, Teresa</creatorcontrib><creatorcontrib>Burchett, Sandra K.</creatorcontrib><creatorcontrib>Opheim, Kent</creatorcontrib><creatorcontrib>Coombs, Robert</creatorcontrib><creatorcontrib>Corey, Lawrence</creatorcontrib><title>Pharmacokinetic Disposition of Zidovudine during Pregnancy</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Zidovudine pharmacokinetics was determined in three human immunodeficiency virus type I-seropositive women receiving zidovudine (200 mg orally every 4 h) from 19 to 39 weeks ofpregnancy and postpartum. Zidovudine concentrations were measured using high-pressure liquid chromatography, and pharmacokinetic analyses were done using model-independent methods. For the pregnant versus postpartum periods, peak zidovudine levels (mean ± 1 SD) were 3.9 ± 1.7 µmol/l versus 4.3 ± 0.04 µmol/l (P = .56); elimination half-lives were 1.3 ± 0.6 versus 1.0 ± 0.3 h (P = .41); areas under the concentration curve were 4.5 ± 1.0 µmol/l × hand 6.8 ± 0.5 µmol/l × h (P = .02); apparent total body clearances were 2.5 ± 0.6/1h/kg and 1.7 ± 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 ± 1.0 1/kg and 2.6 ± 0.81/kg (P = .07), respectively. Umbilical cord serum levels ranged from 113%–127% of maternal levels. No persistent adverse effects of zidovudine therapy were seen in the three women or their babies.</description><subject>Adult</subject><subject>AIDS</subject><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antigens</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Blood plasma</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Dosage</subject><subject>Female</subject><subject>Fetal Blood - chemistry</subject><subject>Half lives</subject><subject>Half-Life</subject><subject>HIV</subject><subject>HIV Infections - metabolism</subject><subject>HIV Infections - prevention & control</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infants</subject><subject>Major Articles</subject><subject>Medical sciences</subject><subject>Pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Postpartum Period - metabolism</subject><subject>Pregnancy</subject><subject>Pregnancy - metabolism</subject><subject>Pregnancy Complications, Infectious - metabolism</subject><subject>Zidovudine - pharmacokinetics</subject><subject>Zidovudine - therapeutic use</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkDtvFDEURi0ECkugp0GaAtHN5toePy4dCo9FRCJIIEVpLI_HDk52xxt7BpF_j9EsSUl1i_PdUxxCXlJYU0B-EscwxHJCJV-zNWPyEVlRwVUrJeWPyQqAsZZqxKfkWSnXANBxqY7IEUWtBagVeXv-0-addekmjn6Krnkfyz6VOMU0Nik0l3FIv-ahwmaYcxyvmvPsr0Y7urvn5Emw2-JfHO4x-fHxw_fTTXv29dPn03dnres0TK3vlBI62IF1MmjUHFDoHrx3jGoaZAhU9egQHWO9s6ofmOghCN31gdpe8GPyZvHuc7qdfZnMLhbnt1s7-jQXo6FjyAT775BWp0YFdQjL0OVUSvbB7HPc2XxnKJi_Xc3S1dSuhpnatb68OrjnfueHh4clZOWvD9wWZ7ch10JV8G_WoVQU1YPmukwp32MOlDEUWHm78Fgm__ue23xjpOJKmM3FpcFvX_Big8II_gftV5pj</recordid><startdate>19910201</startdate><enddate>19910201</enddate><creator>Watts, D. Heather</creator><creator>Brown, Zane A.</creator><creator>Tartaglione, Teresa</creator><creator>Burchett, Sandra K.</creator><creator>Opheim, Kent</creator><creator>Coombs, Robert</creator><creator>Corey, Lawrence</creator><general>The University Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19910201</creationdate><title>Pharmacokinetic Disposition of Zidovudine during Pregnancy</title><author>Watts, D. Heather ; Brown, Zane A. ; Tartaglione, Teresa ; Burchett, Sandra K. ; Opheim, Kent ; Coombs, Robert ; Corey, Lawrence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-e47758fad246f89830958b0eec2181f6ff17b9c99c22bca7bd25b0f584bf1ab53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>AIDS</topic><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antigens</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Blood plasma</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Dosage</topic><topic>Female</topic><topic>Fetal Blood - chemistry</topic><topic>Half lives</topic><topic>Half-Life</topic><topic>HIV</topic><topic>HIV Infections - metabolism</topic><topic>HIV Infections - prevention & control</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infants</topic><topic>Major Articles</topic><topic>Medical sciences</topic><topic>Pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Postpartum Period - metabolism</topic><topic>Pregnancy</topic><topic>Pregnancy - metabolism</topic><topic>Pregnancy Complications, Infectious - metabolism</topic><topic>Zidovudine - pharmacokinetics</topic><topic>Zidovudine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Watts, D. Heather</creatorcontrib><creatorcontrib>Brown, Zane A.</creatorcontrib><creatorcontrib>Tartaglione, Teresa</creatorcontrib><creatorcontrib>Burchett, Sandra K.</creatorcontrib><creatorcontrib>Opheim, Kent</creatorcontrib><creatorcontrib>Coombs, Robert</creatorcontrib><creatorcontrib>Corey, Lawrence</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Watts, D. Heather</au><au>Brown, Zane A.</au><au>Tartaglione, Teresa</au><au>Burchett, Sandra K.</au><au>Opheim, Kent</au><au>Coombs, Robert</au><au>Corey, Lawrence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic Disposition of Zidovudine during Pregnancy</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1991-02-01</date><risdate>1991</risdate><volume>163</volume><issue>2</issue><spage>226</spage><epage>232</epage><pages>226-232</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>Zidovudine pharmacokinetics was determined in three human immunodeficiency virus type I-seropositive women receiving zidovudine (200 mg orally every 4 h) from 19 to 39 weeks ofpregnancy and postpartum. Zidovudine concentrations were measured using high-pressure liquid chromatography, and pharmacokinetic analyses were done using model-independent methods. For the pregnant versus postpartum periods, peak zidovudine levels (mean ± 1 SD) were 3.9 ± 1.7 µmol/l versus 4.3 ± 0.04 µmol/l (P = .56); elimination half-lives were 1.3 ± 0.6 versus 1.0 ± 0.3 h (P = .41); areas under the concentration curve were 4.5 ± 1.0 µmol/l × hand 6.8 ± 0.5 µmol/l × h (P = .02); apparent total body clearances were 2.5 ± 0.6/1h/kg and 1.7 ± 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 ± 1.0 1/kg and 2.6 ± 0.81/kg (P = .07), respectively. Umbilical cord serum levels ranged from 113%–127% of maternal levels. No persistent adverse effects of zidovudine therapy were seen in the three women or their babies.</abstract><cop>Chicago, IL</cop><pub>The University Chicago Press</pub><pmid>1988507</pmid><doi>10.1093/infdis/163.2.226</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1991-02, Vol.163 (2), p.226-232 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80429252 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing |
| subjects | Adult AIDS AIDS/HIV Antibiotics. Antiinfectious agents. Antiparasitic agents Antigens Antiviral agents Biological and medical sciences Blood Blood plasma Chromatography, High Pressure Liquid Dosage Female Fetal Blood - chemistry Half lives Half-Life HIV HIV Infections - metabolism HIV Infections - prevention & control Humans Infant, Newborn Infants Major Articles Medical sciences Pharmacokinetics Pharmacology. Drug treatments Postpartum Period - metabolism Pregnancy Pregnancy - metabolism Pregnancy Complications, Infectious - metabolism Zidovudine - pharmacokinetics Zidovudine - therapeutic use |
| title | Pharmacokinetic Disposition of Zidovudine during Pregnancy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A29%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20Disposition%20of%20Zidovudine%20during%20Pregnancy&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Watts,%20D.%20Heather&rft.date=1991-02-01&rft.volume=163&rft.issue=2&rft.spage=226&rft.epage=232&rft.pages=226-232&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/163.2.226&rft_dat=%3Cjstor_proqu%3E30122959%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15848970&rft_id=info:pmid/1988507&rft_jstor_id=30122959&rfr_iscdi=true |